文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET/CT在骨肉瘤复发检测中的作用

The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-12

该回顾性研究纳入37例经充分手术治疗并达完全缓解后临床怀疑复发的骨肉瘤患者,评估18F-FDG PET/CT的诊断准确性。按患者分析灵敏度91%、特异度75%、准确率89%、阳性预测值97%、阴性预测值50%;局部复发检测的灵敏度96%、特异度100%,肺转移检测的灵敏度80%、特异度100%。作者认为18F-FDG PET/CT对检测骨肉瘤复发有价值,尤其对局部复发和肺转移。

要点

  • 37例骨肉瘤疑似复发患者中,18F-FDG PET/CT阳性率为89.2%(33/37),组织学阳性率为92%(34/37)。
  • 按患者分析:灵敏度91%、特异度75%、准确率89%、阳性预测值97%、阴性预测值50%。
  • 局部复发检测:灵敏度96%、特异度100%、准确率97%;肺转移检测:灵敏度80%、特异度100%、准确率92%。

核心结论

  • 18F-FDG-PET/CT在检测治疗后疑似复发的骨肉瘤患者复发灶方面显示出有价值的结果,尤其在检测局部复发和肺转移方面。

研究设计与样本

  • 回顾性纳入37例符合全部入选标准的患者(男20例、女17例),原发手术治疗为切除31例、截肢6例。
  • 纳入标准:经证实骨肉瘤的充分手术治疗且治疗后记录完全缓解;随访中因临床/诊断怀疑复发而行18F-FDG-PET/CT;对疑似病灶行新手术治疗并切除;18F-FDG-PET/CT结果经组织学验证。
  • 按患者和按部位评估灵敏度、特异度、准确率、阳性预测值(PPV)和阴性预测值(NPV),复发部位分为局部、肺、淋巴结(LNs)和远处(其他骨骼节段和/或远处软组织)。
  • 评估18F-FDG PET/CT后的无病生存(DFS)和总生存(OS)。

主要发现

  • 18F-FDG-PET/CT阳性者占89.2%(33/37);仅局部摄取者占35.1%(13/37),仅肺摄取者占18.9%(7/37),仅远处摄取者占2.7%(1/37),多部位摄取者占32.4%(12/37)。
  • 组织学阳性者占92%(34/37);共评估51个病理病灶(局部复发22个、肺转移11个、转移性淋巴结10个、远处转移病灶8个)。
  • 按患者分析:灵敏度91%、特异度75%、准确率89%、PPV 97%、NPV 50%。
  • 按部位分析:局部复发检测的灵敏度、特异度、准确率、PPV、NPV分别为96%、100%、97%、100%、93%;肺复发检测分别为80%、100%、92%、100%、88%。
  • 18F-FDG PET/CT后平均随访21.5个月,末次随访时19%(7/37)患者带病死亡、38%(14/37)带病存活、43%(16/37)无疾病证据;24个月和60个月总生存率分别为90%和75%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of this study was to investigate the diagnostic accuracy of 18F-FDG-PET/CT in osteosarcoma patients suspicious for disease recurrence after adequate surgical therapy. METHODS: Inclusion criteria were: a) adequate surgical treatment for proven osteosarcoma and documented complete remission after therapy; b) 18F-FDG-PET/CT performed during follow-up for clinical/diagnostic suspicion of relapse; c) new surgical treatment with excision of the suspected lesions; d) histological validation of 18F-FDG-PET/CT findings. Thirty-seven patients matching all inclusion criteria were retrospectively enrolled (20 men and 17 female). Primary surgical treatment consists of resection (31 cases) or amputation (six cases). 18F-FDG-PET/CT performance was assessed with a per-patient and per-site evaluation of sensitivity, specificity, accuracy, positive predicting value (PPV), and negative predicting value (NPV). The sites of relapse were classified as local, lung, lymphnodes (LNs), and distant (other skeletal segments and/or distant soft tissue). The disease-free survival (DFS) and the overall survival (OS) after 18F-FDG PET/CT were evaluated. RESULTS: 18F-FDG-PET/CT was positive in 89.2% (33/37) of patients. Local uptake only was observed in 35.1% patients (13/37); lung uptake only in 18.9% (7/37); distant uptake only in 2.7% (1/37) case; multiple sites of uptake in 32.4% (12/37). Histology resulted positive in 92% (34/37) of patients. A total of 51 pathologic lesions were evaluated (22 local relapse, 11 lung metastasis, 10 metastatic LNs, eight distant metastatic lesions). On a per-patient analysis 18F-FDG-PET/CT showed a sensitivity, specificity, accuracy, PPV, and NPV of 91%, 75%, 89%, 97%, 50%. On a per-site analysis the performance for local relapse was 96%, 100%, 97%, 100%, 93%, while for lung relapse detection was 80%, 100%, 92%, 100%, 88%. The mean follow-up after 18F-FDG-PET/CT was 21.5 months. At the last follow-up, 19% (7/37) of patients were death with disease, 38% (14/37) were alive with disease, and 43% (16/37) had no evidence of disease. Overall survival was 90% and 75% at 24 and 60 months, respectively. CONCLUSION: 18F-FDG-PET/CT showed valuable results for detecting recurrence(s) in osteosarcoma patients with suspicious of relapse after treatment, particularly in the detection of local relapse and lung metastasis.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Angelini A, Ceci F, Castellucci P, et al. The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. Eur J Nucl Med Mol Imaging. 2017. PMID: 28405727. doi:10.1007/s00259-017-3698-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。